Busy week at ADA 2026. Results for Survodutide, a GL1/GCGR agonist are out (SYNCHRONIZE-1 Trial). You can find the paper on NEJM, but I wanted to highlight the body composition results from this trial, for people concerned about excessive lean mass loss, and what we can expect from other GCGR agonists like retatrutide.
A prespecified body composition substudy was conducted using MRI to evaluate how survodutide affects specific fat depots and muscle mass compared to placebo.
The analysis was performed on a subgroup of 75 participants (24.9% of whom were evenly split with 25 participants in each of the three trial groups: survodutide 3.6 mg, survodutide 6.0 mg, and placebo). These participants were taking their assigned regimen at week 76, had no previous treatment interruptions, and had complete data available at both baseline and week 76.
Ectopic and Total Fat Reductions
The trial highlights that survodutide led to dose-dependent reductions in body fat, particularly targeting visceral and liver fat.
1. Liver Fat Content
- Survodutide 6.0 mg: Achieved a dramatic relative reduction of -63.1% in liver fat content from baseline to week 76.
- Survodutide 3.6 mg: Achieved a relative reduction of -46.0%.
- Placebo: Experienced a relative reduction of -24.5%.
2. Visceral Fat Volume
Visceral fat surrounds internal organs and is heavily linked to metabolic risk. Survodutide showed substantial clearing of this depot:
- Survodutide 6.0 mg: Led to a relative reduction of -34.0% (an absolute decrease of 1.9 liters).
- Survodutide 3.6 mg: Led to a relative reduction of -29.8% (an absolute decrease of 1.6 liters).
- Placebo: Led to a relative reduction of -11.8% (an absolute decrease of 0.7 liters).
3. Subcutaneous and Total Fat Volume
- Subcutaneous Fat: Reduced by -28.1% (8.0 liters) in the 6.0-mg group and -23.0% (7.2 liters) in the 3.6-mg group, compared to -9.8% (3.2 liters) with placebo.
- Total Fat Volume: Reduced by -27.8% (10.9 liters) in the 6.0-mg group and -22.9% (9.7 liters) in the 3.6-mg group, compared to -9.5% (4.1 liters) with placebo.
Lean Body Volume and Lean Loss Ratio
When individuals lose weight rapidly, they often lose lean body mass (muscle) alongside fat. The MRI substudy tracked lean body volume changes to assess the quality of the weight loss:
- Absolute Lean Loss: The 6.0-mg group lost an average of 2.7 liters of lean volume, the 3.6-mg group lost 1.9 liters, and the placebo group lost 0.8 liters.
- Relative Lean Loss: This equated to a -9.8% relative reduction in lean volume for the 6.0-mg group and a -7.2% reduction for the 3.6-mg group, compared to -2.9% for placebo.
- Lean Loss Ratio: The lean loss ratio calculates the correlation between the loss of lean tissue mass and total tissue mass. The trial reported highly consistent ratios across all groups: 10.8% for the 6.0-mg group, 11.1% for the 3.6-mg group, and 12.8% for the placebo group.
Clinical Significance of the Findings
The trial investigators noted that most standard exercise regimens and existing weight-loss pharmacotherapies do not preferentially target visceral and liver fat. They speculated that the unique mechanism of survodutide—specifically the glucagon receptor activation, which stimulates hepatic lipolysis (the breakdown of fat in the liver)—is responsible for these stark reductions in liver and visceral fat.
Notably, while the 3.6-mg and 6.0-mg doses resulted in similar overall weight loss in the main trial, the 6.0-mg dose appeared to be noticeably more effective at reducing liver fat content (-63.1% vs -46.0%), suggesting distinct metabolic advantages at higher doses.
In the context of significant medical weight loss, a lean loss ratio of 10% to 11% is considered excellent. The fact that survodutide achieved a lean loss ratio of 10.8% (at the 6.0-mg dose) and 11.1% (at the 3.6-mg dose) indicates a high “quality” of weight loss, meaning the medication exceptionally preserved muscle mass while preferentially burning off fat. Interestingly, this was even slightly lower than the lean loss ratio of the placebo group (12.8%), further demonstrating that the dual-agonist mechanism safely targeted fat stores without accelerating muscle wasting.